-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan

Benzinga·09/29/2026 07:30:02
Diffusion vocale
  • Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks
  • These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg